SWAN, 1953 - Google Patents

Miotic Therapy of Chronic Glaucoma—Changing Trends

SWAN, 1953

Document ID: 3064500865880110102
Author: SWAN K
Publication year: 1953
Publication venue: AMA Archives of Ophthalmology

External Links

Cited by

Snippet

THERE are exciting developments in glaucoma research, but the medical treatment of noninflammatory types of chronic glaucoma continues to be primarily with drugs which induce miosis in the normal eye. In recent years, much has been learned about these drugs; …

Continue reading at jamanetwork.com (other versions)

230000003547 miosis 0 title abstract description 51

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Method or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears

Similar Documents

Publication	Publication Date	Title
Ewing et al.	1990	Needle revision with and without 5-fluorouracil for the treatment of failed filtering blebs
Sun et al.	2016	Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term
Robin et al.	1987	Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy
Hoskins Jr et al.	1983	Complications of laser trabeculoplasty
Korey et al.	1982	Central corneal endothelial cell density and central corneal thickness in ocular hypertension and primary open-angle glaucoma
Kaiser et al.	1993	Systemic blood pressure in glaucoma patients
Shields et al.	1994	Noncontact transscleral Nd: YAG cyclophotocoagulation: a long-term follow-up of 500 patients
Ruiz et al.	1987	Management of increased intraocular pressure after cataract extraction
Hollands et al.	1987	The effect of acetylcholine on early postoperative intraocular pressure
US20030225041A1 (en)	2003-12-04	Physiological method of improving vision
Goldberg et al.	1980	Timolol and epinephrine: a clinical study of ocular interactions
US4904649A (en)	1990-02-27	Method and solution for treating glaucoma
US5212168A (en)	1993-05-18	Method of and solution for treating glaucoma
Nebbioso et al.	2018	Intracameral lidocaine as supplement to classic topical anesthesia for relieving ocular pain in cataract surgery
Jampol et al.	1976	Pathways of the eye's response to topical nitrogen mustard.
Flammer et al.	1983	The effect of a number of glaucoma medications on the differential light threshold
Jawad et al.	2016	Changes of intraocular pressure in vitrectomised eyes after removal of silicone oil
SWAN	1953	Miotic Therapy of Chronic Glaucoma—Changing Trends
SWAN et al.	1951	Competitive action of miotics on the iris sphincter
Akaishi et al.	2005	Continuous monitoring of circadian variations in intraocular pressure by telemetry system throughout a 12-week treatment with timolol maleate in rabbits
Langham	1971	Role of adrenergic mechanisms in development and therapy of open-angled glaucoma
RU2303449C1 (en)	2007-07-27	Method for treatment of diabetic maculoretinopathy edematous form
BLOOMFIELD	1947	Relative deficiency of parasympathomimetic activity in aqueous of eyes with chronic simple glaucoma
SCHEIE	1950	GLAUCOMA: A Review of the Literature, 1949-1950
Kim et al.	1994	Effects of intracameral carbachol and acetylcholine on early postoperative intraocular pressure after cataract extraction.